Dr. N Nikolov #FDA reviews role for rheum meds in #COVID19 and outlines guidance for trial design for CV19 therapeutics #ACR20 @rheumnow https://t.co/0oPvBN5mgF

We need to work together with our patients to ensure medication adherence during this pandemic. 1⃣30% of 734 pts on DMARDs changed their med use during COVID 2⃣Med change without physician guidance 3⃣Changes resulted in ⬆️steroid use @RheumNow #ACR20 Abs#L05 https://t.co/n18zqed4wC

@rheumNow #ACR20 #ABSL02 registry data: Pts on biologics more likely to Shield at Home during COVID 19 as opposed to non-biologic or no systemic Rx at all. Such stringent mitigation tactics may contribute to the reported lower risk of adverse COVID-19 outcomes in biologics Pts

@uptoTate @RheumNow It is only when I started working more closely with our rheum team to look at improving services did I realise how high no-shows are ! We have a 2yr waiting list so these appts are like gold dust. Unfortunately telemedicine not a viable option for your 1st rheum appt.

Frequency and Anatomic Distribution of MRI Lesions in the Sacroiliac Joints of Healthy Subjects and Patients with Spondyloarthritis. Dr Hecquet. #ACR20 @RheumNow BME was seen in 65% patients with Spa and in 20% without spondyloarthritis predominantly in the antero-middle quadrant https://t.co/OUYz2FQ5Yp

Important work by Dr. Winthrop on influenza AEs in Tofacinitib patients - similar among 5mg/10mg BID, only 2 deaths/~500 cases, both with H1N1 and co-morbid RFs. Abst#L04 @RheumNow #ACR20 https://t.co/7MZYGv8W3i

Do you have a problem with no-shows? #ABS1584 discusses telemedicine and care access during COVID-19. Case Western observed a 0% cancellation rate, <10% no-show rate, & 90% of scheduled telemed visits completed during COVID-19. #ACR20 #ACRbest @RheumNow https://t.co/uxzpfELDBG https://t.co/U2qrOTJZOq

• Risk Factors for Adverse Pregnancy Outcomes in Women with Spondyloarthritis: An…

Abst#L01. Pt is on MTX/ADA for RA and asks you about their COVID risk. What do you counsel your patient? #ACR20 @RheumNow.

I just reviewed the #ACR20 talk regarding vaccination. Highly recommended/timely given data released from Pfizer today regarding the COVID-19 vaccine trial. ⁦@RheumNow⁩ Pfizer’s Early Data Shows Vaccine Is More Than 90% Effective - The New York Times https://t.co/Fb5ZepCBeJ

• https://www.nytimes.com/2020/11/09/health/covid-vaccine-pfizer.html